Pinealon 10mg, Research Peptide Canada

Buy Pinealon in Canada from Anglo Peptides, a Canadian research-grade supplier of the short peptide bioregulator Pinealon. Every vial is produced in a cGMP-compliant facility, independently verified to ≥99% purity by third-party HPLC, and lyophilised for stability. Orders ship same-day in cold-pack packaging, arrive within 1 to 3 business days across Canada, and include a batch-specific certificate of analysis. The summary below reflects the published preclinical literature and is provided for laboratory research context only.

What Is Pinealon?

Pinealon is a synthetic tripeptide with the sequence glutamic acid-aspartic acid-arginine (Glu-Asp-Arg, often abbreviated EDR). It belongs to the family of short peptide bioregulators developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in Russia, a group associated with research into brain and pineal regulation. It is commonly listed with CAS number 175175-23-2, molecular formula C15H26N6O8 and a molecular weight of roughly 418 g/mol, though these chemical identifiers are repeated mainly across secondary sources rather than a primary database and should be treated as commonly reported. A minority of sources list an alternative sequence, so the predominant designation, Glu-Asp-Arg, is the one used here.

Mechanism of Action

The proposed mechanism for Pinealon comes almost entirely from the originating research group and should be read as a hypothesis supported largely by modelling and that group’s own assays rather than as established fact.

Cell and nuclear interaction. Very short peptides are proposed to enter cells, reach the nucleus, and interact with histones and DNA, binding complementarily to specific promoter sequences. Evidence cited for this includes molecular-docking studies of the EDR peptide with short DNA sequences.^[3]

Gene-expression and antioxidant signalling. The peptide is proposed to modulate transcription and, in neuronal models, to influence the ERK1/2 pathway, reduce pro-apoptotic proteins such as caspase-3 and p53, and support antioxidant enzymes.^[3][5]

It is important to note that direct, sequence-specific binding to genomic sites in living human cells is a mechanistic proposal, not a firmly established phenomenon.

Research Applications

All published findings for Pinealon are preclinical, carried out in cell culture and rodent models; there is no robust human clinical-trial evidence.

Antioxidant and cell-viability research. In cerebellar granule cells and other cultures under oxidative stress, Pinealon was reported to restrict reactive-oxygen-species accumulation, reduce necrotic cell death, and alter ERK1/2 activation and the cell cycle.^[1]

Neuroprotection in rodent models. In offspring of rats subjected to experimental prenatal stress, maternal Pinealon was reported to improve spatial learning and make neurons more resistant to oxidative stress.^[2]

Neuroplasticity in Alzheimer models. The EDR peptide, alongside related tripeptides, was reported to reduce loss of dendritic spines in an Alzheimer’s-model mouse, with mechanism explored through molecular docking.^[3][4]

State of the evidence. The body of work is preclinical, concentrated within one research group, and human data are limited. Pinealon should be regarded as an investigational research compound and is supplied for laboratory use only.

Stability, Solubility and Handling

Anglo Peptides supplies Pinealon as a lyophilised powder. For research it is reconstituted with sterile or bacteriostatic water, in which this short peptide is readily soluble. Store the lyophilised powder sealed, desiccated and protected from light, with long-term storage at -20°C; keep reconstituted solution refrigerated and use within a few weeks, avoiding repeated freeze-thaw cycles. These notes apply to in-vitro and animal research only.

Product Specifications

• Compound: Pinealon (Glu-Asp-Arg, EDR), short peptide bioregulator
• Sequence: Glu-Asp-Arg
• CAS: 175175-23-2 (commonly reported)
• Molecular formula: C15H26N6O8 (commonly reported)
• Molecular weight: ~418 g/mol
• Purity: ≥99% by HPLC
• Size: 10 mg per vial
• Form: Lyophilised powder
• Testing: Independent third-party HPLC and mass spectrometry
• Documentation: Batch-specific certificate of analysis
• Origin: Made in Canada

Quality, Testing and Canadian Sourcing

Every batch of Anglo Peptides Pinealon is independently tested to ≥99% purity with a lot-specific certificate of analysis. Producing and finishing vials in Canada lets us verify the full labelled milligram content and ship quickly without customs delays. Read more on our Canadian sourcing page. Researchers studying the Khavinson short-peptide bioregulators often examine Pinealon alongside Epithalon and Thymalin.

Pinealon Within the Khavinson Peptide Family

Pinealon belongs to a group of very short peptides developed in St. Petersburg and collectively described as peptide bioregulators or cytogens. The central idea behind the family is that peptides of only two to four residues might act as signalling molecules that influence gene expression in a tissue-associated manner, with different short sequences linked to different organ systems. Pinealon, the tripeptide Glu-Asp-Arg, is positioned within this framework as a brain- and pineal-associated regulator, studied alongside related sequences from the same program. For researchers, the value of Pinealon is largely as a representative of this bioregulator hypothesis: it provides a defined, low-molecular-weight tool for examining the proposed link between short peptides and cellular responses such as oxidative-stress resistance and gene-expression modulation. It should be studied with the understanding that the surrounding theory remains specific to its originating group and is not broadly established in independent literature.

Considerations for Research Use

Because the Pinealon evidence base is preclinical and concentrated within one research program, study design benefits from explicit caution. Mechanistic claims about direct DNA or promoter binding rest substantially on molecular modelling and that group internal assays, so experiments intended to test those claims independently should include appropriate negative controls and, where possible, orthogonal readouts rather than relying on a single endpoint. Dose-response work should be built from the concentrations reported in the primary cell-culture and rodent studies rather than assumed. As with any short peptide, confirmation of identity by mass spectrometry and verification of purity for each lot are essential, since an impure or under-dosed preparation will distort results. Every Anglo Peptides batch ships with third-party HPLC verification and a lot-specific certificate of analysis.

Reconstitution, Storage and Handling in Detail

For laboratory use, the lyophilised powder is typically brought to room temperature before opening to avoid condensation, then reconstituted by adding sterile or bacteriostatic water slowly down the inside wall of the vial rather than directly onto the powder, and swirled gently rather than shaken to limit foaming and shear stress. The choice of diluent depends on the study: sterile water is common for single-session work, while bacteriostatic water, which contains a small amount of benzyl alcohol, is often preferred when a solution will be drawn from over several days. Once reconstituted, the solution is kept refrigerated at 2 to 8 degrees Celsius, protected from light, and used within a defined window, with aliquoting into single-use portions the most reliable way to avoid the repeated freeze-thaw cycles that degrade peptides. The lyophilised powder itself is far more stable than any solution and is best stored frozen, sealed and desiccated, for long-term holding. These are general research-handling conventions; the lot-specific certificate of analysis and its storage guidance should always take precedence for a given batch.

Frequently Asked Questions

References

1. Khavinson V, Ribakova Y, Kulebiakin K, et al. Pinealon Increases Cell Viability by Suppression of Free Radical Levels and Activating Proliferative Processes. Rejuvenation Res. 2011;14(5):535-541. DOI
2. Arutjunyan A, Kozina L, Stvolinskiy S, et al. Pinealon protects the rat offspring from prenatal hyperhomocysteinemia. Int J Clin Exp Med. 2012;5(2):179-185. PubMed
3. Khavinson V, Linkova N, Kozhevnikova E, Trofimova S. EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer’s Disease. Molecules. 2020;26(1):159. PubMed
4. Khavinson V, Ilina A, Kraskovskaya N, et al. Neuroprotective Effects of Tripeptides – Epigenetic Regulators in Mouse Model of Alzheimer’s Disease. Pharmaceuticals (Basel). 2021;14(6):515. PubMed
5. Khavinson VK, Popovich IG, Linkova NS, et al. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. PubMed

Research use only. Pinealon supplied by Anglo Peptides is intended exclusively for licensed laboratory and academic research. It is not a drug, dietary supplement, or medical product, and is not for human consumption, diagnosis, or treatment.

Researchers who buy Pinealon from Anglo Peptides receive a vial verified to ≥99% purity, batch-tested by Janoshik Labs, and shipped from within Canada. Choose the 10mg size above.